IN2014DN04647A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN04647A IN2014DN04647A IN4647DEN2014A IN2014DN04647A IN 2014DN04647 A IN2014DN04647 A IN 2014DN04647A IN 4647DEN2014 A IN4647DEN2014 A IN 4647DEN2014A IN 2014DN04647 A IN2014DN04647 A IN 2014DN04647A
- Authority
- IN
- India
- Prior art keywords
- unsubstituted
- substituted
- alkenyl
- alkyl
- single bond
- Prior art date
Links
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004419 alkynylene group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001556 benzimidazoles Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1119538.5A GB201119538D0 (en) | 2011-11-10 | 2011-11-10 | Pharmaceutical compounds |
| PCT/GB2012/052806 WO2013068769A1 (en) | 2011-11-10 | 2012-11-12 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN04647A true IN2014DN04647A (pl) | 2015-05-15 |
Family
ID=45421672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4647DEN2014 IN2014DN04647A (pl) | 2011-11-10 | 2012-11-12 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9809575B2 (pl) |
| EP (1) | EP2776416B1 (pl) |
| JP (1) | JP6046735B2 (pl) |
| KR (1) | KR101996335B1 (pl) |
| CN (1) | CN104144921B (pl) |
| CA (1) | CA2855204C (pl) |
| CY (1) | CY1117428T1 (pl) |
| DK (1) | DK2776416T3 (pl) |
| ES (1) | ES2568476T3 (pl) |
| GB (1) | GB201119538D0 (pl) |
| HR (1) | HRP20160374T1 (pl) |
| HU (1) | HUE028747T2 (pl) |
| IN (1) | IN2014DN04647A (pl) |
| PL (1) | PL2776416T3 (pl) |
| RU (1) | RU2612530C2 (pl) |
| SI (1) | SI2776416T1 (pl) |
| WO (1) | WO2013068769A1 (pl) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY172021A (en) * | 2012-10-16 | 2019-11-12 | Janssen Sciences Ireland Uc | Rsv antiviral compounds |
| EP2997028A1 (en) * | 2013-05-14 | 2016-03-23 | F.Hoffmann-La Roche Ag | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection |
| CN105408330A (zh) * | 2013-08-12 | 2016-03-16 | 豪夫迈·罗氏有限公司 | 新的用于治疗和预防呼吸道合胞病毒感染的氮杂-氧代-吲哚 |
| JP6211195B2 (ja) | 2013-08-12 | 2017-10-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 呼吸器合胞体ウイルス感染症の処置および予防のための新規アザ−オキソ−インドール |
| HK1222855A1 (zh) * | 2013-08-15 | 2017-07-14 | F. Hoffmann-La Roche Ag | 新的用於治疗和预防呼吸道合胞病毒感染的氮杂-氧代-吲哚 |
| US9850251B2 (en) | 2013-12-10 | 2017-12-26 | Shandong Danhong Pharmaceutical Co., Ltd. | Imidazole derivative used as antiviral agent and use therof in preparation of medicament |
| TWI671299B (zh) * | 2014-04-14 | 2019-09-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 作為ｒｓｖ抗病毒化合物之螺脲化合物 |
| GB201417707D0 (en) * | 2014-10-07 | 2014-11-19 | Viral Ltd | Pharmaceutical compounds |
| EP3298017B1 (en) | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
| ES2821649T3 (es) | 2015-06-08 | 2021-04-27 | Shangdong Danhong Pharmaceutical Co Ltd | Método para preparar derivados de imidazol e intermedios de los mismos y formas cristalinas |
| JP6659841B2 (ja) | 2015-11-12 | 2020-03-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための組成物 |
| WO2017097728A1 (en) | 2015-12-10 | 2017-06-15 | F. Hoffmann-La Roche Ag | Bridged piperidine derivatives |
| IL294124B2 (en) | 2015-12-10 | 2024-02-01 | Ptc Therapeutics Inc | Methods for treating huntington's disease |
| ES2878058T3 (es) | 2016-08-04 | 2021-11-18 | Reviral Ltd | Derivados de pirimidina y su uso en el tratamiento y la prevención de una infección por virus respiratorio sincitial |
| US11407753B2 (en) | 2017-06-05 | 2022-08-09 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| WO2019005993A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| US11382918B2 (en) | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
| GB201711704D0 (en) * | 2017-07-20 | 2017-09-06 | Reviral Ltd | Pharmaceutical compounds |
| GB201721812D0 (en) | 2017-12-22 | 2018-02-07 | Reviral Ltd | Pharmaceutical compounds |
| MX2020009957A (es) | 2018-03-27 | 2021-01-15 | Ptc Therapeutics Inc | Compuestos para el tratamiento de enfermedad de hungtinton. |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| PL3814357T3 (pl) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics, Inc. | Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona |
| EP3814345B8 (en) | 2018-06-27 | 2024-10-30 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| WO2020231977A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN117343019A (zh) * | 2022-06-29 | 2024-01-05 | 焦作市沃恩生物科技有限责任公司 | 一种4,7-二氮杂螺[2.5]辛烷-4-甲酸叔丁酯的制备方法 |
| WO2024174953A1 (zh) * | 2023-02-21 | 2024-08-29 | 苏州隆博泰药业有限公司 | 苯并咪唑类衍生物及其医药用途 |
| WO2024252355A1 (en) | 2023-06-08 | 2024-12-12 | Pfizer Inc. | Pediatric dosing regimens comprising a fusion inhibitor for the treatment of rsv |
| WO2025120500A1 (en) | 2023-12-06 | 2025-06-12 | Pfizer Inc. | Benzodiazepine compounds as n-protein inhibitors |
| WO2025153942A1 (en) | 2024-01-16 | 2025-07-24 | Pfizer Inc. | Benzodiazepine pyrazolo carboxamides as n-protein inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4044136A (en) | 1972-09-09 | 1977-08-23 | Pfizer Inc. | Aminoquinazoline therapeutic agents |
| PL194216B1 (pl) * | 1998-01-23 | 2007-05-31 | Sankyo Co | Pochodne spiropiperydyny, lekarstwo oraz środek zapobiegawczy lub terapeutyczny zawierające jako składnik czynny te pochodne i zastosowanie pochodnych spiropiperydyny |
| SI1196408T1 (en) | 1999-06-28 | 2005-02-28 | Janssen Pharmaceutica N.V. | Respiratory syncytial virus replication inhibitors |
| US6369076B1 (en) * | 1999-10-29 | 2002-04-09 | Merck & Co. Inc. | 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists |
| US6774134B2 (en) | 2000-12-20 | 2004-08-10 | Bristol-Myers Squibb Company | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
| PA8535601A1 (es) * | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| US6919331B2 (en) * | 2001-12-10 | 2005-07-19 | Bristol-Myers Squibb Company | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents |
| NZ551468A (en) | 2003-12-24 | 2010-05-28 | Biota Scient Management | Polycyclic agents for the treatment of respiratory syncytial virus infections |
| US20100278835A1 (en) | 2009-03-10 | 2010-11-04 | Astrazeneca Uk Limited | Novel compounds 660 |
| WO2011069298A1 (en) | 2009-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | Novel cyclopropane indolinone derivatives |
-
2011
- 2011-11-10 GB GBGB1119538.5A patent/GB201119538D0/en not_active Ceased
-
2012
- 2012-11-12 PL PL12787847T patent/PL2776416T3/pl unknown
- 2012-11-12 DK DK12787847.8T patent/DK2776416T3/en active
- 2012-11-12 JP JP2014540557A patent/JP6046735B2/ja active Active
- 2012-11-12 ES ES12787847.8T patent/ES2568476T3/es active Active
- 2012-11-12 WO PCT/GB2012/052806 patent/WO2013068769A1/en not_active Ceased
- 2012-11-12 HR HRP20160374TT patent/HRP20160374T1/hr unknown
- 2012-11-12 EP EP12787847.8A patent/EP2776416B1/en active Active
- 2012-11-12 RU RU2014123434A patent/RU2612530C2/ru active
- 2012-11-12 SI SI201230521A patent/SI2776416T1/sl unknown
- 2012-11-12 CN CN201280066542.8A patent/CN104144921B/zh active Active
- 2012-11-12 KR KR1020147015742A patent/KR101996335B1/ko active Active
- 2012-11-12 CA CA2855204A patent/CA2855204C/en active Active
- 2012-11-12 US US14/357,293 patent/US9809575B2/en active Active
- 2012-11-12 IN IN4647DEN2014 patent/IN2014DN04647A/en unknown
- 2012-11-12 HU HUE12787847A patent/HUE028747T2/en unknown
-
2016
- 2016-04-12 CY CY20161100308T patent/CY1117428T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140308282A1 (en) | 2014-10-16 |
| GB201119538D0 (en) | 2011-12-21 |
| EP2776416A1 (en) | 2014-09-17 |
| RU2014123434A (ru) | 2015-12-20 |
| KR20140128292A (ko) | 2014-11-05 |
| CN104144921B (zh) | 2016-08-24 |
| PL2776416T3 (pl) | 2017-01-31 |
| WO2013068769A1 (en) | 2013-05-16 |
| JP2014533257A (ja) | 2014-12-11 |
| EP2776416B1 (en) | 2016-01-13 |
| KR101996335B1 (ko) | 2019-07-04 |
| CY1117428T1 (el) | 2017-04-26 |
| SI2776416T1 (sl) | 2016-06-30 |
| DK2776416T3 (en) | 2016-04-18 |
| HRP20160374T1 (hr) | 2016-06-03 |
| ES2568476T3 (es) | 2016-04-29 |
| CN104144921A (zh) | 2014-11-12 |
| HUE028747T2 (en) | 2016-12-28 |
| US9809575B2 (en) | 2017-11-07 |
| CA2855204A1 (en) | 2013-05-16 |
| CA2855204C (en) | 2020-06-16 |
| JP6046735B2 (ja) | 2016-12-21 |
| RU2612530C2 (ru) | 2017-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN04647A (pl) | ||
| SV2010003598A (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa | |
| BRPI0716598A2 (pt) | Derivados de (hetero) arilsulfonamida de n-biarila úteis no tratamento de doenças medidas por interações de linfócitos | |
| WO2009026176A3 (en) | Antiinfective flavononol compounds and methods of use thereof | |
| MX2020009511A (es) | Tratamiento o prevención de eventos cardiovasculares. | |
| MX378354B (es) | Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas. | |
| MX338114B (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
| AR047529A1 (es) | Compuestos de quinolina sustituidos | |
| IN2012DN00765A (pl) | ||
| SV2010003483A (es) | Pirimidinas biciclicas fusionadas | |
| JO2673B1 (en) | New diosmetin compounds, a process for their preparation and pharmaceutical compositions containing them | |
| MX361458B (es) | Compuestos de pirimido-piridazinona y uso de los mismos. | |
| AR066191A1 (es) | Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona | |
| PE20110215A1 (es) | Derivados de 4,5-dihidro-oxazol-2-ilo | |
| PH12015502429A1 (en) | Dicarboxylic acid compound | |
| UY32404A (es) | 4-aril-butan-1,3-diamidas | |
| ECSP099506A (es) | Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos | |
| PE20150349A1 (es) | Derivado de benzodioxol y metodos de preparacion y uso del mismo | |
| EP2612848A4 (en) | CYCLIC AMID DERIVATIVES | |
| CR20110256A (es) | [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos | |
| MX2011011716A (es) | Derivados de isoquinolina novedosos. | |
| EA201270277A1 (ru) | N-ацилированные октасахариды, активирующие рецепторы fgf, их получение и применение в терапии | |
| IN2012DN01251A (pl) | ||
| EP2604261A3 (en) | SCCA-1 production inhibitor having a carboxamide derivative and/or a salt thereof as an active ingredient | |
| MX2012013589A (es) | Derivados de 2-amino pirimidina utiles como inhibidores de cinasas del extremo n-terminal de c-jun (jnk). |